1. A new molecular classification to drive precision treatment strategies in primary Sjögren's syndrome
- Author
-
Agence Nationale de la Recherche (France), European Commission, Soret, P., Le Dantec, C., Desvaux, E., Foulquier, N., Chassagnol, B., Hubert, S., Jamin, C., Barturen, Guillermo, Desachy, G., Devauchelle-Pensec, V., Boudjeniba, C., Cornec, D., Saraux, A., Jousse-Joulin, S., Barbarroja, N., Rodríguez-Pintó, I., De Langhe, E., Beretta, L., Chizzolini, C., Kovács, L., Witte, T., PRECISESADS Clinical Consortium, PRECISESADS Flow Cytometry Consortium, Bettacchioli, E., Buttgereit, A., Makowska, Z., Lesche, R., Borghi, M. O., Martín, J., Courtade-Gaiani, S, Xuereb, L., Guedj, M, Moingeon, P., Alarcón-Riquelme, M. E., Laigle, L., Pers, Jacques-Olivier, Agence Nationale de la Recherche (France), European Commission, Soret, P., Le Dantec, C., Desvaux, E., Foulquier, N., Chassagnol, B., Hubert, S., Jamin, C., Barturen, Guillermo, Desachy, G., Devauchelle-Pensec, V., Boudjeniba, C., Cornec, D., Saraux, A., Jousse-Joulin, S., Barbarroja, N., Rodríguez-Pintó, I., De Langhe, E., Beretta, L., Chizzolini, C., Kovács, L., Witte, T., PRECISESADS Clinical Consortium, PRECISESADS Flow Cytometry Consortium, Bettacchioli, E., Buttgereit, A., Makowska, Z., Lesche, R., Borghi, M. O., Martín, J., Courtade-Gaiani, S, Xuereb, L., Guedj, M, Moingeon, P., Alarcón-Riquelme, M. E., Laigle, L., and Pers, Jacques-Olivier
- Abstract
There is currently no approved treatment for primary Sjögren’s syndrome, a disease thatprimarily affects adult women. The difficulty in developing effective therapies is -in part-because of the heterogeneity in the clinical manifestation and pathophysiology of the disease.Finding common molecular signatures among patient subgroups could improve our under-standing of disease etiology, and facilitate the development of targeted therapeutics. Here,we report, in a cross-sectional cohort, a molecular classification scheme for Sjögren’s syn-drome patients based on the multi-omic profiling of whole blood samples from a Europeancohort of over 300 patients, and a similar number of age and gender-matched healthyvolunteers. Using transcriptomic, genomic, epigenetic, cytokine expression andflow cyto-metry data, combined with clinical parameters, we identify four groups of patients withdistinct patterns of immune dysregulation. The biomarkers we identify can be used bymachine learning classifiers to sort future patients into subgroups, allowing the re-evaluationof response to treatments in clinical trials.
- Published
- 2021